Fulvestrant Injection, Solution
Product Images NDC 16714-070

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 16714-070). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx, Llc,, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton-label.jpg (Carton Label)

This is a description of a medication called Fulvestrant Inject, which is available in a package with NDC number 16714-070-02. It is an injection that contains 250 mg of Fulvestrant per 5 ml (50 mg/mL) and is intended for intramuscular use only. The last line of text is not legible.*

FDA Label Image

Figure-1 (Fulvestrant Inj Fig 1)

FDA Label Image

Figure-10 (Fulvestrant Inj Fig 10)

FDA Label Image

Figure-11 (Fulvestrant Inj Fig 11)

This appears to be a chart displaying the Progression-Free Survival Probability for two groups of patients. The first group (N=446) received a combination of FULVESTRANT and Abemaciclib, while the second group (N=223) only received FULVESTRANT plus Placebo. The chart displays the probability of progression-free survival over time in months, with the x-axis displaying time in months and the y-axis displaying the percentage of patients expected to survive progression-free. However, without more context or information it is difficult to interpret the chart fully or what disease or condition was being studied.*

FDA Label Image

Figure-12 (Fulvestrant Inj Fig 12)

The given text is a survival probability chart showing patients who received FULVESTRANT with Abemaciclib and FULVESTRANT with Placebo. The chart is plotted over time in months and shows the number of patients alive in both groups. There were 446 patients who received FULVESTRANT with Abemaciclib and 223 patients who received FULVESTRANT with Placebo. The observations of 100 patients are censored. Censored observations are those patients who were lost to follow-up or did not experience an event within the duration of the study.*

FDA Label Image

Figure-13 (Fulvestrant Inj Fig 13)

FDA Label Image

Figure-14 (Fulvestrant Inj Fig 14)

FDA Label Image

Figure-2 (Fulvestrant Inj Fig 2)

FDA Label Image

Figure-3 (Fulvestrant Inj Fig 3)

FDA Label Image

Figure-4 (Fulvestrant Inj Fig 4)

FDA Label Image

Figure-5 (Fulvestrant Inj Fig 5)

FDA Label Image

Figure-6 (Fulvestrant Inj Fig 6)

This is a survival analysis table showing the number of individuals at risk over time for two different doses of Fulvestrant (a type of medication used to treat breast cancer). However, without information on the event being studied (such as death or disease progression) it is difficult to provide further context.*

FDA Label Image

Figure-7 (Fulvestrant Inj Fig 7)

FDA Label Image

Figure-8 (Fulvestrant Inj Fig 8)

FDA Label Image

Figure-9 (Fulvestrant Inj Fig 9)

FDA Label Image

Structure (Fulvestrant Inj Structure)

FDA Label Image

Container-label.jpg (Vial Label)

This is a description of a medication called Fulvestrant Injection that comes in a 250 mg/5 mL (50 mg/mL) dose, and is for single-use only. The medication should be protected from light and both single-dose prefilled syringes must be used to receive the 500 mg dose. The text also includes information about the manufacturer and lot number of the medication.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.